1. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Issue 10328 (5th March 2022) Authors: McGarvey, Lorcan P; Birring, Surinder S; Morice, Alyn H; Dicpinigaitis, Peter V; Pavord, Ian D; Schelfhout, Jonathan; Nguyen, Allison Martin; Li, Qing; Tzontcheva, Anjela; Iskold, Beata; Green, Stuart A; Rosa, Carmen La; Muccino, David R; Smith, Jaclyn A Journal: Lancet Issue: Volume 399:Issue 10328(2022) Page Start: 909 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. (20th April 2021) Authors: van der Heijde, Désirée; Dougados, Maxime; Maksymowych, Walter P; Bergman, Gina; Curtis, Sean P; Tzontcheva, Anjela; Huyck, Susan; Philip, George; Sieper, Joachim Journal: Rheumatology Issue: Volume 61:Number 2(2022) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects. Issue 2 (April 2015) Authors: Hastrup, Nina; Khalilieh, Sauzanne; Dale, David C.; Hanson, Lars G.; Magnusson, Peter; Tzontcheva, Anjela; Tseng, Jack; Huyck, Susan; Rosenberg, Elizabeth; Krogsgaard, Kim Journal: Cytokine Issue: Volume 72:Issue 2(2015) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗